Product Description
(Sourced from: https://newleos.com/pipeline/)
Mechanisms of Action: GABAA1 PAM
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Newleos
Company Location: Europe
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 0: Generalized anxiety disorder
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
04/01/2026 |
News Article |
Newleos Announces Dosing of First Participant in U.K. Phase 1b Study of NTX-1955 in Generalized Anxiety Disorder |
|
01/06/2026 |
News Article |
Newleos Therapeutics Announces Dosing of First Participant in SOAR Phase 2 Study of NTX-1472 for Social Anxiety Disorder |
|
10/21/2025 |
News Article |
Newleos Therapeutics Appoints Timothy Noyes as President and Chief Executive Officer |
|
09/30/2025 |
News Article |
Newleos Therapeutics Announces Clinical Progress Across Neuropsychiatric Pipeline |